Skip to content
TrackPodcasts
scienceOct 27, 201625:20pending

How TwoXAR Is Using Big Data to Accelerate Drug Discovery

The Bio Report

About this episode

It can take up to six years to accumulate enough evidence to support advancing an experimental drug into clinical development. twoXAR is working to rapidly accelerate that process through the use of Big Data and its proprietary algorithms to find screen large public and proprietary data sets to indentify new drug candidates and determine their efficacy. We spoke to Andrew Radin, co-founder and CEO of twoXAR, about the company’s technology, how it’s being applied today, and the evolution of the company’s strategy.

Get every episode summarized

Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

How TwoXAR Is Using Big Data to Accelerate Drug Discovery

The Bio Report

0:00
25:20

More episodes

More from The Bio Report

View all episodes →